ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Puerarin‑Loaded pH‑Responsive ZIF‑90 Nanoparticles Ameliorate Osteoporosis via Enhancing H3K18 Lactylation and Suppressing Aberrant Osteoclast Activation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoporosis is characterized by dysregulated osteoclast activity, leading to excessive bone resorption and structural damage. In this study, we developed pH-responsive ZIF-90 nanoparticles loaded with puerarin (PU) (ZIF-90@PU) for microenvironment-responsive osteoporosis therapy through epigenetic modulation. Following self-assembly, the nanoparticles underwent dynamic light scattering (DLS), field emission scanning electron microscopy (FE-SEM), powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), and X-ray photoelectron spectroscopy (XPS); these analyses verified efficient puerarin encapsulation and pH-triggered release. In cell-based experiments, ZIF-90@PU suppressed the differentiation of bone marrow-derived macrophages (BMMs) into osteoclasts while promoting osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs). Administration of ZIF-90@PU to ovariectomized (OVX) mice produced significant gains in bone mineral density, trabecular architecture, and bone strength without detectable toxicity. Mechanistically, ZIF-90@PU treatment was associated with increased H3K18 lactylation and reduced NFATc1 signaling, accompanied by suppression of osteoclast activation. This study introduces ZIF-90@PU as a novel epigenetic-modulating nanomedicine for osteoporosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.